1. Home
  2. COEP vs LITB Comparison

COEP vs LITB Comparison

Compare COEP & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • LITB
  • Stock Information
  • Founded
  • COEP 2017
  • LITB 2007
  • Country
  • COEP United States
  • LITB Singapore
  • Employees
  • COEP N/A
  • LITB N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • LITB Catalog/Specialty Distribution
  • Sector
  • COEP Health Care
  • LITB Consumer Discretionary
  • Exchange
  • COEP Nasdaq
  • LITB Nasdaq
  • Market Cap
  • COEP 32.4M
  • LITB N/A
  • IPO Year
  • COEP N/A
  • LITB N/A
  • Fundamental
  • Price
  • COEP $10.45
  • LITB $1.00
  • Analyst Decision
  • COEP
  • LITB
  • Analyst Count
  • COEP 0
  • LITB 0
  • Target Price
  • COEP N/A
  • LITB N/A
  • AVG Volume (30 Days)
  • COEP 60.3K
  • LITB 21.6K
  • Earning Date
  • COEP 05-09-2025
  • LITB 03-24-2025
  • Dividend Yield
  • COEP N/A
  • LITB N/A
  • EPS Growth
  • COEP N/A
  • LITB N/A
  • EPS
  • COEP N/A
  • LITB N/A
  • Revenue
  • COEP N/A
  • LITB $333,093,000.00
  • Revenue This Year
  • COEP N/A
  • LITB N/A
  • Revenue Next Year
  • COEP N/A
  • LITB N/A
  • P/E Ratio
  • COEP N/A
  • LITB N/A
  • Revenue Growth
  • COEP N/A
  • LITB N/A
  • 52 Week Low
  • COEP $2.31
  • LITB $0.91
  • 52 Week High
  • COEP $13.70
  • LITB $6.00
  • Technical
  • Relative Strength Index (RSI)
  • COEP 48.25
  • LITB 41.05
  • Support Level
  • COEP $10.00
  • LITB $0.92
  • Resistance Level
  • COEP $11.75
  • LITB $1.05
  • Average True Range (ATR)
  • COEP 1.07
  • LITB 0.05
  • MACD
  • COEP -0.12
  • LITB 0.01
  • Stochastic Oscillator
  • COEP 48.22
  • LITB 61.54

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: